Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy
Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland
Subjects
More information
Scope and Contents
Contents
Introduction: IgE-mediated bee venom allergy can be treated with allergen-specific immunotherapy (AIT). Subcutaneous immunotherapy (SCIT) is time and cost intensive due to the repeated consultations, but the costs are justified by the high risk of potentially life-threatening allergic reactions, including anaphylaxis. However, intralymphatic immuno...
Alternative Titles
Full title
Potential Cost Savings by Switching from Subcutaneous to Intralymphatic Insect Venom Immunotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2840249002
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2840249002
Other Identifiers
ISSN
1018-2438
E-ISSN
1423-0097
DOI
10.1159/000531332
